CRISPR Therapeutics -10.4%: fresh sell signal
CRISPR Therapeutics sheds 10.4%: sell signal strength hits the ceiling at 100
CRISPR Therapeutics -10.4%: fresh sell signal
Our view last week
CRISPR Therapeutics technical analysis flags a rough week: the stock fell 11.2%, with sellers taking nearly all of the volume and money flow swinging back into negative territory. Price is now boxed into a very tight band, between the first resistance in the 53.5 area and the first support in the 53.3 area, not far from the old double bottom in the 50 area. Last week the residual capital was still in the green; now it's back underwater.
This week's summary
After last week's 11.2% drop, CRISPR Therapeutics stock sheds another 10.4% and a fresh Sell signal triggers: price is now boxed in between the double bottom in the 48 area and the first resistance just above, in the 47.8 area. Signal strength hits the ceiling, 100 out of 100 — "downtrend making lower lows, pace holding" — on a highly volatile name. This week's technical analysis places CRISPR Therapeutics 6th among the 140 US sell signals; the quality band flags trading as not recommended.
IQS Phase
67
in tension
Signal Strength
100
downtrend making lower lows, pace holding
Sizing
STANDARD
Ranking
#6 / 140
New us stocks
Trade P&L %
+0.00%
from signal to today
restricted Platinum content